Brazil approves emergency use  for China COVID-19 inactivated vaccine

Brazil approves emergency use  for China COVID-19 inactivated vaccine. The government will distribute the COVID-19 vaccine to all parts of the country and launch the COVID-19 vaccination campaign at 10 o’clock on the 20th.

On January 17, local time, Brazil’s National Health Supervision Agency announced that it had granted emergency use permits for the COVID-19vaccine developed by China Kexing Company.

△The Brazilian National Bureau of Health Supervision granted emergency use permission for China’s Coxing COVID-19 vaccine (picture source: Brazilian National News Agency)

At the press conference held on the same day, Gustave Santos, the head of the Pharmaceutical and Biological Products Department of the Brazilian Health Inspection Agency, and Fabrizio Oliveira, the coordinator of the Pharmaceutical Inspection Department, gave a detailed introduction to COVID-19 of Crevo The vaccine’s research and development process, production process, storage conditions, and the results of the third phase of the test in Brazil.

Both experts said that the COVID-19 vaccine from Kerrlive is safe, effective and easy to store. The collegiate council of Brazil’s National Health Inspection Agency, composed of five experts, including the director of Brazil’s National Health Inspection Agency, Antonio Torres, voted in favor of the emergency use of the COVID-19 vaccine. In the state of Sao Paulo, the state with the largest number of confirmed cases in Brazil, there are currently 6 million doses of Kellyford’s COVID-19 vaccine available for injection.

In addition, Brazil’s Minister of Health Eduardo Pazulo also announced on the same day that the government will distribute the COVID-19 vaccine to all parts of the country starting at 7 o’clock on January 18, and will fully launch the COVID-19 vaccination campaign at 10 o’clock on the 20th.

Phase III results of previous Kexing inactivated vaccines in Brazil

Reuters has continuously reported the protection data of Coxing’s COVID-19 inactivated virus vaccine CoronaVac. The latest CoronaVac clinical trial protection in Indonesia is 65.3%; while Brazil has released updated data, showing the protection of CoronaVac is 50.38%.

In summary, CoronaVac’s protective power in clinical trials in Turkey is 91.25%, in Indonesia it is 65.3%, and in Brazil it is 50.38%.

Yesterday Reuters reported the interim analysis data of CoronaVac’s Phase III clinical trial released by Indonesia’s national drug regulatory agency BPOM. It pointed out that the vaccine has a protective effect of 65.3%, but did not give details of the clinical trial. Penny K. Lukito, the head of BPOM, pointed out that this protective power meets the requirements of the World Health Organization (>50%), so the agency approved the listing of CoronaVac in Indonesia. Kexing will provide 330 million vaccines to Indonesia in the next 15 months.

Today, Reuters reported the “general efficacy” (overall effect) data in the late stage of the Brazilian clinical trial, stating that the overall effect was 50.38%. Ricardo Palacios, director of the Butantan Institute, which conducts the CoronaVac clinical trial in Brazil, pointed out that 50.38% of the results are based on the analysis of the final results by including mild SARS-CoV-2 infections (the press conference specifically pointed out that these infections are not asymptomatic infections) .

There was a live broadcast of the conference on Twitter, and the link can be seen in the comments. At the press conference, the data released by Ricardo Palacios dispelled many people’s doubts about the calculation of the vaccine’s protective power. He pointed out that there are currently 4,653 people in the vaccination group and 4,599 people in the placebo group. In the current analysis, 183 people in the vaccination group were infected; 363 people in the placebo group were infected. The resulting population protection power was 50.38% (p=0.0049).

The Butantan Institute has published three CoronaVac data. The CoronaVac’s protection against symptomatic COVID-19 announced last week was 78%, but in the data released today, Ricardo Palacios said that the 77.96% protection announced last week The force is based on CoronaVac’s prevention of infected patients who require medical intervention and hospitalization (see comments for the live Twitter link). Therefore, 50.38% is the comprehensive result of CoronaVac’s prevention of symptomatic COVID-19, which is currently the largest protective data of CoronaVac samples.

Therefore, the current protective power of CoronaVac in clinical trials in Turkey is 91.25%, 65.3% in Indonesia, and 50.38% in Brazil. These data indicate that Kexing needs CoronaVac to further publish detailed phase III clinical trial data

(source:internet, reference only)

Disclaimer of medicaltrend.org